|
gptkbp:instanceOf
|
gptkb:antibiotic
cephalosporin
|
|
gptkbp:approvalYear
|
1982
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
J01DD04
|
|
gptkbp:brand
|
gptkb:Rocephin
|
|
gptkbp:CASNumber
|
73384-59-5
|
|
gptkbp:chemicalFormula
|
beta-lactam ring
|
|
gptkbp:contraindication
|
hypersensitivity to cephalosporins
neonates with hyperbilirubinemia
|
|
gptkbp:discoveredBy
|
gptkb:Hoffmann-La_Roche
|
|
gptkbp:eliminationHalfLife
|
6-9 hours
|
|
gptkbp:excretion
|
renal
biliary
|
|
gptkbp:hasInChIKey
|
QJYFOTNNEUZCHN-GZKRHAGFSA-N
|
|
gptkbp:hasMolecularFormula
|
C18H18N8O7S3
|
|
gptkbp:hasSMILES
|
O=C2N1/C(=C(\\CS[C@@H]1[C@@H]2NC(=O)C(=N\\OC)/c3nc(sc3)N)COC(=O)O)C
|
|
gptkbp:hasUNII
|
5W6315QWIQ
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ceftriaxonum
|
|
gptkbp:KEGGID
|
D00255
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits bacterial cell wall synthesis
|
|
gptkbp:molecularWeight
|
554.58 g/mol
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL521
4589542
5479530
DB01212
|
|
gptkbp:routeOfAdministration
|
intramuscular
intravenous
|
|
gptkbp:sideEffect
|
diarrhea
rash
allergic reactions
gallbladder pseudolithiasis
|
|
gptkbp:spectrumOfActivity
|
broad-spectrum
|
|
gptkbp:treatment
|
gptkb:pneumonia
meningitis
sepsis
urinary tract infections
gonorrhea
otitis media
intra-abdominal infections
skin and soft tissue infections
bone and joint infections
|
|
gptkbp:usedFor
|
bacterial infections
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:ceftriaxone
gptkb:Ceftriaxone
|
|
gptkbp:bfsLayer
|
6
|